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Abstract  
 
Background 
The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing. The aim was to 
provide reference survival data for patients with advanced iCCA treated with first-line 
cisplatin-gemcitabine chemotherapy (current standard of care). 
Methods 
Individual data from patients with iCCA recruited into the prospective, randomised Advanced 
Biliary tract Cancer (ABC)-01, -02 and -03 studies were retrieved. The prevalence and 
survival of liver-only iCCA was also assessed. Survival analysis was performed using 
univariate and multivariable Cox Regression.  All statistical tests were two-sided. 
Results 
Of 534 patients recruited into the ABC-01, -02 and -03 studies, 109 (20.4%) had iCCA. Most 
patients (n=86; 78.9%) had metastatic disease at the time of recruitment; 52 patients (47.7%) 
had liver-only disease. Following randomisation, 66 (60.6%) iCCA patients received 
cisplatin/gemcitabine. The median progression-free (PFS) and overall survival (OS) was 8.4 
months (95%confdence interval [CI] = 5.9-8.9) and 15.4 months (95%CI = 11.1-17.9), 
respectively. Of these 66 patients, 34 patients (51.5%) had liver-only disease. Following 
chemotherapy, 30 (45.5%) and 21 (31.8%) were progression free at 3 and 6 months from 
chemotherapy commencement, respectively. Median OS for patients with liver-only iCCA at 
diagnosis, and after 3 and 6 months of chemotherapy was 16.7 months (95% confidence 
interval [CI] = 8.7-20.2), 17.9 (95%CI = 11.7-20.9) and 18.9 (95%CI = 16.7-25.9) months, 
respectively. Multivariable analysis confirmed that iCCA had a longer OS compared to other 
non-iCCA BTCs (hazard ratio = 0.58, 95%CI = 0.35-0.95; p-value = 0.03); liver-only iCCA 
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patients also showed longer OS even though findings did not reach statistical significance 
(hazard ratio = 0.65, 95%CI = 0.36-1.19; p-value = 0.16). 
Conclusions 
Patients diagnosed with advanced iCCA have a better OS compared to other BTCs; similar 
trend was identified for patients diagnosed with liver-only iCCA. These findings are to be 
considered for future clinical trial design. 
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Biliary tract cancers (BTCs) include cholangiocarcinoma (intrahepatic (iCCA), hilar 
and distal), gallbladder and ampullary carcinoma (1). BTCs are usually diagnosed in patients 
aged 50 to 70 years (2) and prognosis is poor (1, 3, 4). Although considered rare(2), their 
incidence is increasing due to a clinically significant rise in diagnosis of iCCA (5-7).  
Systemic chemotherapy is the only treatment approach that demonstrated survival 
benefit in randomised phase III studies for advanced BTC (8, 9). Cisplatin/gemcitabine is 
currently accepted as a reference first-line treatment in advanced BTC in many countries (8) 
based on the ABC-02 phase III clinical trial (10). These findings were confirmed in a 
Japanese randomised phase II study (BT22 study) (11) with no quality of life detriment in the 
combination arm identified (12). Other first-line chemotherapy options are under 
development (13-16). Role of second-line chemotherapy remains unclear (17-22), and 
suitable only for around 15% of patients due to rapidly-worsening performance status (19). 
Results of a randomised phase III study in this setting  are awaited (23).  
iCCA is considered a separate entity from other BTCs, due to anatomical and 
molecular characteristics (9). iCCAs have been identified to express specific targetable 
genetic aberrations such as fibroblast growth factor receptor (FGFR) fusion rearrangements 
(9, 24-29) and isocitrate dehydrogenase (IDH)-1 and-2 mutations (9, 30-33, 33, 34, 34-37).  
Patients with iCCA are more likely to have liver-only disease. For such scenarios, 
liver-directed therapies (LDT) are being explored (38) and suggested by some international 
guidelines (39). Methods of intra-arterial therapy include hepatic-arterial-embolisation, trans-
arterial-chemo-embolisation, radio-embolisation (Yttrium90; RE) (40-45) and liver-
chemosaturation (46, 47).  
This post-hoc analysis aimed to provide reference survival data to inform the design, 
sample size calculation and feasibility of future studies exploring the role of systemic 
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(including targeted) therapies and LDT in advanced iCCA. Potential trial designs together 
with factors to consider in designing such studies are discussed. 
 
 
Materials and methods 
Study design 
A post-hoc analysis of patient data collected as part of the prospective ABC-01 (48), -02 (10) 
and -03 (49) clinical trials was performed. These studies explored the role of first-line 
systemic chemotherapy in advanced BTCs (cisplatin/gemcitabine vs. gemcitabine [ABC-01 
and ABC-02] and cisplatin/gemcitabine/cediranib vs. cisplatin/gemcitabine/placebo [ABC-
03]). All patients had provided written consent for participating in the above-mentioned trials, 
published elsewhere (10, 48-49) . The studies were sponsored by University College of 
London and coordinated by the Cancer Research UK & UCL Cancer Trials Centre, which 
facilitated access to anonymised individual-patient data.  
Patients diagnosed with iCCA were evaluable for this post-hoc analysis. Clinical data, 
including demographics, baseline tumour markers, complete blood count, renal/liver profile, 
treatment characteristics and response/survival data were retrieved. The best radiological 
response achieved by each patient was classified based on the version of Response 
Evaluation Criteria In Solid Tumours (RECIST) employed in each study: RECISTv1.0 (50) 
for ABC-01/-02, RECISTv1.1 (51) for ABC-03.  
The primary aim of this analysis was to provide reference overall survival (OS) data 
of patients diagnosed with iCCA treated with first-line cisplatin/gemcitabine chemotherapy 
for future prospective studies. The sub-group of patients diagnosed with iCCA who were 
potentially eligible for LDT (defined as patients with liver-only disease) were analysed 
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separately. Secondary objectives included progression-free survival (PFS); description of 
demographic data of patients diagnosed with iCCA; and assessment of the frequency of 
iCCA patients with liver-only disease. Suitability for LDT at 3 and 6 months required 
meeting the above-mentioned criteria for LDT, and being progression-free at 3 and 6 months 
following chemotherapy commencement, respectively. 
 
Statistical analysis 
All eligible patients were included in the analysis. All patients diagnosed with iCCA were 
included for a summary of baseline characteristics. For survival analysis, only patients treated 
with the combination of cisplatin/gemcitabine were included (current standard of care for 
good-performance status patients). Since the addition of cediranib to cisplatin/gemcitabine 
did not result in a statistically-significant impact on survival in the ABC-03 study (49), 
patients receiving both cediranib and placebo were included in the survival analysis of 
patients treated with cisplatin/gemcitabine. 
PFS and OS were measured as the time from randomisation to progression/death or 
death of any cause, respectively. Patients who did not experience a PFS or OS event were 
censored at the date of last follow-up. Calculations of PFS and OS using as a starting point 3 
and 6 months from randomisation were performed to identify patients potentially suitable for 
LDT at 3 and 6 months, respectively. Survival analysis was performed with Kaplan-Meier 
method and Cox Regression (univariate and multivariable analysis including variables 
statistically significant in the univariate analysis (defined as p-value <0.05); Ph test was used 
to test for proportional-hazards assumption. For identification of prognostic factors, derived 
Hazard Ratio (HR), 95% confidence intervals (CI) and p-values were reported. Stata v.12 
software was employed. P-values <0.05 were considered statistically significant. All 
statistical tests were two-sided. 
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Results 
Study population 
Data from a total of 534 patients was retrieved (86, 324, and 124 patients from the ABC-01, 
ABC-02, and ABC-03 studies, respectively). Although the ABC-02 clinical trial reported a 
total of 410 patients, 86 were patients previously recruited into the ABC-01; such patients 
were included only once in this study. Thus, 324 patients from ABC-02 were eligible for this 
post-hoc analysis. Of the whole population of eligible BTC patients, 318 (59.6%) were 
diagnosed with cholangiocarcinoma: 109 (20.4% of the whole population) had iCCA. By the 
end of follow-up, 82.9% of the whole population had died. The results are provided 
according to the cohorts specified in Supplementary Figure 1. 
 
Whole population of patients diagnosed with BTC 
Baseline characteristics are shown in Table1. Estimated median OS (regardless of type of 
chemotherapy administered; Supplementary Figure 1/CohortA) for the whole population of 
534 patients was 10.3 months (95%CI = 8.8-11.7). When only patients receiving 
cisplatin/gemcitabine were included, the median PFS and OS were 7.9 months (95%CI = 6.8-
8.4) and 12.2 months (95%CI = 10.7-13.6) (Figure 1A), respectively.  
 
Whole iCCA population: baseline characteristics and chemotherapy treatment  
The characteristics of all patients diagnosed with iCCA (109 patients; Supplementary 
Figure 1/CohortB) are summarised in Table1. Most of the patients with iCCA had 
metastatic disease (n=86; 78.9%); 52 patients (47.7%) had no extrahepatic metastases. 
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Of the 109 patients diagnosed with iCCA, 19, 61 and 29 patients were treated within 
the ABC-01, ABC-02 and ABC-03 clinical trials, respectively. Following study entry, 43 
(39.5%) and 66 (60.6%) patients received gemcitabine or cisplatin/gemcitabine combination, 
respectively. Of the 66 patients who received cisplatin/gemcitabine chemotherapy 
(Supplementary Figure 1/CohortC), 14 also received cediranib as per the ABC-03 study 
protocol (49). Within these 66 patients (Supplementary Figure 1/CohortC), one patient 
(1.5%) achieved a complete radiological response. In addition, 15 (22.7%) and 26 (39.4%) 
patients achieved a partial response and stable disease as best response, respectively. Eleven 
patients (16.7%) had progression and 13 did not undergo radiological assessment. 
Supplementary Table 1 summarises absolute responses achieved at each time-point 
explored; response rate for iCCA population was similar to the one showed for patients with 
non-iCCA BTC (Supplementary Table 2).  
Estimated median OS (regardless of type of chemotherapy administered; 
Supplementary Figure 1/CohortB) for all patients diagnosed with iCCA was 12.6 months 
(95%CI = 8.7-15.2) respectively. When only patients receiving cisplatin/gemcitabine were 
included (Table2; Supplementary Figure 1/CohortC), the median PFS and OS for all 
patients diagnosed with iCCA were 8.4 (95%CI = 5.9-8.9) and 15.4 months (95%CI = 11.1-
17.9) (Figure 1B), respectively. Patients diagnosed with iCCA had statistically significant 
longer OS when compared to other BTCs (iCCA vs. BTC [non-iCCA, reference group] 
univariate HR = 0.72, 95%CI = 0.53-0.98; p-value = 0.04 (Figure 1B); multivariable analysis 
for OS is shown in Supplementary Table 3 (adjusted multivariable HR = 0.58, 95%CI 0.35-
0.95; p-value = 0.03). Further detail regarding PFS and OS rates at a number of time-points is 
provided in Table2 (data for additional time-points can be found in Supplementary Table 
4). No statistically significant differences in PFS were identified between iCCA (median = 
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8.4, 95%CI = 5.9-8.9) and non-iCCA BTC patients (median = 7.9, 95%CI = 6.5-8.4); log 
rank p-value = 0.65. 
 
Subgroup of patients with liver-only disease 
Fifty-two patients diagnosed with iCCA had liver-only disease (52/109; 47.7%); Table1 
includes baseline characteristics for this patient population (Supplementary Figure 
1/CohortD). Of the 66 patients diagnosed with iCCA receiving cisplatin/gemcitabine 
chemotherapy (Supplementary Figure 1/CohortC), 34 patients (51.5%) had liver-only 
disease at diagnosis (Supplementary Figure 1/CohortE). Of these 34 patients, 7 patients 
(20.6%) achieved a partial response and 17 (50%) had stable disease as best response, which 
accounted for a disease control rate of 70.6%. Of the remaining 10 patients, 7 (20.6%) had 
progression as best response and 3 had no radiological assessment of response, due to clinical 
progression (Supplementary Table 1). Response rate was similar to the one showed for 
patients with non-iCCA BTC (Supplementary Table 2).  
Within these 34 patients, following chemotherapy with cisplatin/gemcitabine 30 
(45.5%) and 21 (31.8%) were progression-free (liver-only disease) at 3 and 6 months, 
respectively. Supplementary Figure 2 summarises the adapted consort diagram. Patients 
diagnosed with liver-only iCCA who were treated with cisplatin/gemcitabine had a 
favourable OS when compared with other BTC subgroups [iCCA (liver-only) vs. BTC (no-
iCCA) (Ref) univariate HR = 0.63, 95%CI = 0.43-0.93, p-value = 0.02] (Figure 1C). 
Multivariable analysis for OS is shown in Supplementary Table 3 and confirmed such trend 
despite not reaching statistical significance (adjusted multivariable HR = 0.65, 95%CI = 0.36-
1.19; p-value = 0.16). 
The median PFS / OS for the subgroup of patients who received cisplatin/gemcitabine 
diagnosed with liver-only iCCA (Supplementary Figure 1/CohortE) at study entry, and 
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following 3 and 6 months from starting chemotherapy was 8.4 months (95%CI = 5.9-10.02) / 
16.7 months (95%CI = 8.7-20.2), 8.6 months (95%CI = 7.6-11.3) / 17.9 months (95%CI = 
11.7-20.9) and 11.1 months (95%CI = 8.5-12.9) / 18.9 months (95%CI = 16.7-25.9), 
respectively (Table2; Supplementary Table 4). Table2 provides further PFS and OS rate 
information at different time-points explored for this patient population (data for additional 
time-points can be found in Supplementary Table 4). No statistically significant differences 
in PFS (measured from study entry) were identified between liver-only iCCA (median = 8.4 
95%CI =5.9-10.0) and non-iCCA BTC patients (median 7.9, 95%CI = 6.5-8.4; log rank p-
value = 0.37). 
 
Prognostic factors  
OS was shorter in patients diagnosed with iCCA and treated with cisplatin/gemcitabine, who 
had a higher serum carcinoembryonic antigen (CEA) levels at baseline. This factor was 
independent prognostic factor on multivariable analysis adjusted for other variables 
statistically significant in the univariate analysis (Table3).  
Multivariable analysis confirmed that higher platelet count and high CEA at baseline 
were associated with shorter OS in the population of patients with iCCA treated with 
cisplatin/gemcitabine with liver-only disease (Table3). Although other factors were impacted 
on OS in the univariate analysis, none were independently prognostic in the multivariable 
analysis. 
 
 
Discussion 
There is an urgent need for additional therapies for patients with BTCs. Patients with iCCA 
represent a specific subgroup for whom novel targeted therapies and LDT are emerging as 
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promising therapeutic options. IDH and FGFR inhibitors have been tested in early phase 
clinical trials, and phase III studies are ongoing aimed at evaluating their efficacy (9). In 
addition, current evidence supporting LDT in iCCA is of limited quality (category C; as per 
‘Standards, Options and Recommendations’ (SOR) guidelines (52)) and therefore phase III 
randomised studies evaluating the impact of adding LDT to current standard of care 
(cisplatin/gemcitabine) chemotherapy are planned in order to confirm previously-suggested 
benefit. This post-hoc analysis of the prospective ABC-01(48), -02(10) and -03(49) clinical 
trials explored the outcome of patients diagnosed with iCCA who were treated with 
cisplatin/gemcitabine chemotherapy in order to inform the design of such studies. 
Patients diagnosed with iCCA had a prolonged OS when compared to the pooled 
patients with BTCs/non-iCCA, which makes them an attractive subgroup for development of 
further treatment approaches . Similar trend was identified when patients diagnosed with 
iCCA with liver-only disease (therefore suitable for LDT) were analysed. Survival may have 
been underestimated by the inclusion of patient with ECOG performance status 2.   
Various findings support the fact that this prolonged OS is reflective of a different 
natural history rather than a better response to palliative chemotherapy (53). Firstly, the 
median PFS for cisplatin/gemcitabine-treated iCCA patients (8.4 months) was similar to the 
one achieved in the ABC-02 clinical trial (mixed population of BTC) [8.0 months (10)]. 
Secondly, this difference in survival is unlikely to be related to a stage shift, since a similar 
percentage of patients with metastatic disease were identified within all patient subgroups 
(76.8%) and within the iCCA subgroup (78.9%). Thirdly, differential molecular findings 
described within iCCA, such FGFR translocations and IDH mutations, have been suggested 
to impact survival(9). As an example, FGFR  translocations [present in around 11-45% of 
iCCAs (9)] in iCCA have been identified as a marker for more indolent behaviour and better 
outcome (33, 34). 
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Regarding the potential role of LDT in patients with iCCA, approximately half of the 
patients with iCCA in the current analysis had liver-only disease and would therefore be 
suitable for LDT. This supports the feasibility of recruiting to future prospective studies 
exploring LDT in this population of patients. Potential trial designs for incorporating LDT to 
the treatment management of patients with iCCA are summarised in Figure2. Options could 
include the incorporation of LDT before any palliative chemotherapy (Figure2; OptionA), 
during chemotherapy (Figure2; OptionB) or at the end of 6 months of chemotherapy 
(Figure2; OptionC). 
This study provides data on LDT-suitability (defined as presence of liver-only 
disease) and survival at different time-points (baseline, 3 months and 6 months), in order to 
explore which time-point would be more feasible to be explored. From the patient 
recruitment point of view, these results suggest that all three time-points would be adequate 
for introduction of LDT into patients’ pathway; although there is a progressive drop in the 
number of eligible patients. OS increases progressively between these three groups, as can be 
expected due to an immortality bias (54). Due to the longer survival of the patient population 
who would be progression-free at 6 months from starting palliative chemotherapy (and 
therefore eligible for LDT at this point), a study incorporating LDT at this time-point would 
require prolonged follow-up with associated increased cost. 
Few ongoing prospective studies are currently exploring the role of novel forms of 
LDT in iCCA, mainly focused on RE (Table4). A phase II single arm prospective study in 
Hong Kong is recruiting 30 patients with iCCA for treatment with RE followed by standard 
chemotherapy (equivalent to Figure2, OptionA) (NCT02167711). A similar design has been 
followed by the randomised phase II SIRCCA clinical trial (NCT02807181) which is 
investigating the use of the cisplatin/gemcitabine combination +/- RE as first-line treatment 
in patients with advanced iCCA. An innovative approach with concomitant chemotherapy 
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and RE (RE will be administered on day 3 or 4 in combination with cisplatin/gemcitabine in 
cycles 1 and 2) is being explored by another phase I study (NCT02512692). One study is 
currently recruiting patients diagnosed with iCCA to explore other LDT approaches such as 
chemo-saturation (NCT03086993).  
While the above aspects will inform sample size calculation and trial design, 
prognostic factors in patients with iCCAs treated with systemic chemotherapy should be 
considered for patient stratification. In a large series of patients with BTC treated with 
cisplatin/gemcitabine, the impact of factors such as haemoglobin, disease status, bilirubin, 
and neutrophils on both PFS and OS was identified and validated (61). The current post-hoc 
analysis did not confirm these results, probably due to limitations of sample size in the 
subgroup analysis presented. Based on the current results, factors such as ECOG performance 
status and baseline CEA should be considered at time of stratification for patients diagnosed 
with iCCA. In addition, retrospective studies including patients treated with LDT 
(specifically with RE), have identified multiple factors impacting survival which should be 
considered at the time of study design for patient stratification. Patients with ECOG 
performance status of 2 have been reported to have worse prognosis when treated with RE 
(42, 56-58), similar trend was identified in the current iCCA population (even though it did 
not reach statistical significance in the multivariable analysis). Other factors contributing to 
worse prognosis include multifocal disease (55), infiltrative morphology (42, 55, 57), bilobar 
disease (55) and liver tumour burden (56, 62). The presence of portal vein thrombosis has 
been reported to have varying impact on prognosis in different studies (42, 55). The presence 
of extra-hepatic disease, if low volume, is not necessarily required as an exclusion criteria 
(58). Most of these previously described prognostic factors, were not explored in the current 
analysis due to lack of available information, and should be considered at the time of RE 
study design.  
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A strength of this work is the fact that all data had been previously produced and 
quality-assured as part of prospective clinical trials. This provides robustness to the results. In 
addition, a homogeneous population of patients treated with the same chemotherapy schedule 
is presented (treatment-naïve patients treated with first-line cisplatin/gemcitabine) and the 
same chemotherapy protocol for dose reductions and duration of chemotherapy. 
Regarding the limitations of this post-hoc analysis, it is worth mentioning that the 
sample size was modest, since the analysis was focused on a small subpopulation of patients, 
which could have limited the survival analysis (particularly the Cox-regression for 
identification of prognostic factors when multiple covariates were included). Some patients 
had received cediranib as part of the ABC-03 study, but this was not expected to impact on 
the patients’ outcomes (49). In addition, the actual percentage of patients suitable for LDT 
may have been under or overestimated due to the lack of information for assessing the above 
criteria, such as tumour spread pattern and technical problems (i.e. liver-lung shunt). In fact, 
only patients with liver-only disease were classified as suitable for LDT, excluding patients 
with liver-predominant disease.  
In summary, the magnitude of benefit described in some of the studies focusing on 
iCCA is within the range that would be considered statistically significant if there was no 
knowledge of the survival of this patient cohort. This post-hoc analysis demonstrates that 
patients with iCCA have a better outcome than other patients with BTC and these survival 
figures should be considered at the time of future study design in this patient population. In 
addition, close to half of the patients diagnosed with iCCA are likely to have liver-only 
disease, and therefore may be suitable for approaches involving LDT.  
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Tables 
 
Table 1: Summary of baseline characteristics of all patients and those with iCCA 
included in ABC-01, -02 and -03. 
Characteristics 
All patients with 
biliary tract 
cancer 
(n=534) 
Intrahepatic 
cholangiocarcinoma 
(n=109) 
Patients with 
iCCA and liver-
only disease 
(n= 52) 
N (%) N (%) N (%) 
Gender    
Female 278 (52.1) 53 (48.6) 23 (44.2) 
Male 256 (47.9) 56 (51.4) 29 (55.8) 
Median age, y (range) 64.3 (23.4-84.8) 61.7 (35.0-78.9) 63.1 (35.3-78.4) 
ECOG Performance Status    
0 185 (34.6) 43 (38.5) 28 (53.9) 
1 297 (55.6) 57 (52.3) 22 (42.3) 
2 52 (9.7) 9 (8.3) 2 (3.8) 
Primary tumour site    
Gallbladder 188 (35.2) n/a n/a 
Ampulla of Vater 28 (5.3) n/a n/a 
Cholangiocarcinoma 318 (59.6) 109 (100) 52 (100) 
iCCA 109 (34.3) 109 (100) 52 (100) 
Extrahepatic 
cholangiocarcinoma 
122 (38.4) n/a 
n/a 
Hilar 57 (17.9) n/a n/a 
Not specified 30 (9.4) n/a n/a 
Grade of Differentiation    
Well differentiated 40 (7.5) 7 (6.4) 2 (3.8) 
Moderately 
differentiated 
164 (30.7) 30 (27.5) 
16 (30.8) 
Poorly differentiated 99 (18.5) 22 (20.2) 12 (23.1) 
Not specified 231 (43.3) 50 (45.9) 22 (42.3) 
Prior treatment    
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No 328 (61.4) 82 (75.2) 38 (73.1) 
Yes  206 (38.6) 27 (24.8) 14 (26.9) 
Surgery 48 (23.3) 10 (37.1) 8 (57.1) 
Other* 158 (76.7) 17 (62.9) 6 (42.9) 
Stented    
No 491 (91.9) 106 (97.3) 50 (96.1) 
Yes  43 (8.1) 3 (2.8) 2 (3.9) 
Stage    
Locally advanced 124 (23.2) 23 (21.1) 23 (44.2) 
Metastatic 410 (76.8) 86 (78.9) 29 (55.8) 
Sites of disease†    
Liver 161 (30.2) 35 (31.1) 52 (100) 
Peritoneum 76 (14.2) 10 (9.2) n/a 
Lung 43 (8.1) 13 (11.9) n/a 
Other 44 (8.2) 11 (10.1) n/a 
Extrahepatic disease    
No 250 (46.8) 52 (47.7) 52 (100) 
Yes 139 (26.0) 28 (25.7) n/a 
Not specified 145 (27.2) 29 (26.6) n/a 
*Other treatment included radiotherapy, and photodynamic therapy. iCCA: intrahepatic 
cholangiocarcinoma; ECOG: Eastern Cooperative Oncology Group; n/a: not applicable. 
† “Site of disease” was missing for some patients. 
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Table 2: Progression-free survival and overall survival of patients with iCCA treated with cisplatin/gemcitabine at various time-points. 
Outcome 
No. of patients 
eligible for LDT 
(liver-only disease)/ 
total (%) 
Median, months 
(95%CI) 
Rate, % (95%CI) 
3 months 6 months 9 months 12 months 18 months 
Progression free survival        
All patients diagnosed with iCCA 
(survival from starting cisplatin 
gemcitabine) 
n/a 8.4 (5.9-8.9) 75.8 (63.5-
84.4) 
61.9 (49.1-
72.5) 
38.1 (26.4-
49.8) 
24.9 (14.9-
36.1) 
11.2 (4.8-
20.5) 
Patients with liver-only iCCA at 
first diagnosis of advanced 
disease (study entry/baseline) 
(survival from starting cisplatin 
gemcitabine) 
34/66 (51.5) 8.4 (5.9-10.02) 88.2 (71.6-
95.4) 
64.3 (45.8-
77.9) 
42.9 (25.9-
58.7) 
24.5 (11.6-
39.9) 
12.3 (3.9-
25.8) 
Patients with liver-only iCCA 
after 3 months of 
cisplatin/gemcitabine first-line 
chemotherapy (survival from 
starting cisplatin gemcitabine) 
30/66 (45.5) 8.6 (7.6-11.3) 100 (100-100) 72.9 (53.0-
85.4) 
48.6 (29.8-
65.1) 
27.8 (13.2-
44.5) 
13.9 (4.4-
28.8) 
Patients with liver-only iCCA 
after 6 months of 
cisplatin/gemcitabine first-line 
chemotherapy (survival from 
starting cisplatin gemcitabine) 
21/66 (31.8) 11.1 (8.5-12.9) 100 (100-100) 100 (100-100) 66.7 (42.5-
82.5) 
38.1 (18.3-
57.8) 
19.1 (5.9-
37.7) 
All BTC n/a 7.9 (6.9-8.4) 79.8 (75.1-
83.8) 
61.8 (56.3-
66.9) 
38.1 (32.1-
44.0) 
20.3 (15.4-
25.6) 
8.8 (5.4-13.0) 
Non-iCCA BTC n/a 7.8 (6.5-8.4) 80.8 (75.5-
85.1) 
61.8 (55.6-
67.4) 
38.1 (32.1-
44.0) 
20.3 (15.4-
25.6) 
8.8 (5.4-13.0) 
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Overall survival        
All patients diagnosed with iCCA 
(survival from starting cisplatin 
gemcitabine) 
n/a 15.4 (11.1-17.9) 90.6 (80.2-
95.6) 
79.4 (67.2-
87.5) 
68.1 (55.0-
78.1) 
61.4 (48.1-
72.2) 
36.5 (24.4-
48.6) 
Patients with liver-only iCCA at 
first diagnosis of advanced 
disease (study entry/baseline) 
(survival from starting cisplatin 
gemcitabine) 
34/66 (51.5) 16.7 (8.7-20.2) 100 (100-100) 81.3 (62.9-
91.1) 
68.8 (49.7-
81.8) 
62.5 (43.5-
76.7) 
43.8 (26.5-
59.8) 
Patients with liver-only iCCA 
after 3 months of 
cisplatin/gemcitabine first-line 
chemotherapy (survival from 
starting cisplatin gemcitabine) 
30/66 (45.5) 17.9 (11.7-20.9) 100 (100-100) 85.7 (66.3-
94.4) 
75.0 (54.6-
87.2) 
67.9 (47.3-
81.8) 
50.0 (30.6-
66.6) 
Patients with liver-only iCCA 
after 6 months of 
cisplatin/gemcitabine first-line 
chemotherapy (survival from 
starting cisplatin gemcitabine) 
21/66 (31.8) 18.9 (16.7-25.9) 100 (100-100) 100 (100-100) 90.5 (67.0-
97.5) 
85.7 (61.9-
95.2) 
61.9 (38.1-
78.8) 
All BTC n/a 12.2 (10.7-13.6) 90.3 (86.4-
93.1) 
77.8 (72.7-
82.0) 
61.7 (55.9-
66.9) 
51.0 (45.1-
56.6) 
27.4 (22.2-
32.9) 
Non-iCCA BTC n/a 11.7 (10.2-12.6) 90.2 (85.7-
93.3) 
77.4 (71.6-
82.1) 
59.9 (53.4-
65.9) 
48.2 (41.5-
54.5) 
24.8 (19.2-
30.9) 
*Median PFS, OS and survival rates have been calculated both from the time of starting palliative chemotherapy. PFS and OS were also 
measured from 3 and 6 months of starting chemotherapy in order to inform all possible trial design sample size calculation (such information can 
be found in Supplementary Table 4). iCCA patients at risk / number of events for each time point are as follows for PFS [at 3 months 66/16; at 
6 months 50/9;at 9 months 40/15; at 12 months 23/8; at 18 months 15/8] and OS [at 3 months 64/6; at 6 months 57/7;at 9 months 50/7; at 12 
months 41/4; at 18 months 36/14]. Data for additional time-points (month 24, 30 and 36) can be found in Supplementary Table 4. CI: 
confidence interval; LDT: liver-directed therapy; iCCA: intrahepatic cholangiocarcinoma; BTC: biliary tract cancer. 
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Table 3: Prognostic factors of overall survival for patients with iCCA treated with cisplatin/gemcitabine 
Factor 
All patients diagnosed with iCCA (n=66) 
Patients diagnosed with iCCA and liver-only disease 
(n=34) 
Univariate analysis Multivariable analysis* Univariate analysis Multivariable analysis* 
HR (95%CI) P† HR (95%CI) P† HR (95%CI) P† HR (95%CI) P† 
Gender         
Female 1.00 (Ref) - - - 1.00 (Ref) - - - 
Male 1.35 (0.79-2.31) 0.28 - - 1.41 (0.67-2.98) 0.37 - - 
Age, y 0.99 (0.97-1.03) 0.91 - - 1.01 (0.97-1.04) 0.99 - - 
ECOG Performance Status         
0 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) - - - 
1 1.43 (0.81-2.55) 0.22 1.11 (0.52-2.37) 0.79 1.59 (0.76-3.32) 0.22 - - 
2 5.21 (1.68-16.19) 0.004 7.54 (0.87-65.21) 0.07 n/a - - - 
Grade of differentiation         
Well differentiated 1.00 (Ref) - - - 1.00 (Ref) - - - 
Moderately differentiated 2.58 (0.33-19.94) 0.36 - - 1.96x109 (7.84x108-
4.89x109) 
<0.001 0.39 (0.08-1.92) 0.25 
Poorly differentiated 3.30 (0.41-26.58) 0.26 - - 2.51x109 (nc) <0.001 nc - 
Prior treatment         
No 1.00 (Ref) - - - 1.00 (Ref) - - - 
Yes  1.02 (0.58-1.79) 0.95 - - 0.79 (0.36-1.76) 0.57 - - 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz071/5488118 by Institute of C
hild H
ealth/U
niversity C
ollege London user on 20 M
ay 2019
Stented         
No 1.00 (Ref) - - - 1.00 (Ref) - - - 
Yes  0.48 (0.11-1.99) 0.31 - - 0.54 (0.07-4.04) 0.55 - - 
Stage         
Locally advanced 1.00 (Ref) - - - 1.00 (Ref) - - - 
Metastatic 1.49 (0.76-2.94) 0.25 - - 1.33 (0.62-2.86) 0.47 - - 
White cell count baseline, × 109/L 1.10 (1.02-1.19) 0.02 0.82 (0.52-1.28) 0.38 1.13 (0.99-1.29) 0.07 - - 
Platelets baseline, × 109/L 1.003 (0.99-1.006) 0.09 - - 1.004 (1.001-1.008) 0.04 1.01 (1.001-1.02) 0.04 
Haemoglobin baseline, g/dL 0.89 (0.75-1.05) 0.17 - - 0.55 (0.36-0.83) 0.005 1.07 (0.56-2.05) 0.83 
Neutrophils baseline, × 109/L 1.16 (1.06-1.26) 0.001 1.69 (0.97-2.96) 0.06 1.17 (1.01-1.34) 0.03 0.99  (0.72-1.37) 0.96 
Bilirubin baseline, μmol/L 1.03 (0.97-1.09) 0.40 - - 0.99 (0.91-1.09) 0.90 - - 
ALT baseline, IU/L 1.01 (0.98-1.02) 0.89 - - 1.01 (0.99-1.02) 0.65 - - 
AST baseline, IU/L 1.001 (0.99-1.01) 0.77 - - 1.01 (0.99-1.03) 0.46 - - 
CEA‡ baseline, μg/L 1.05 (1.02-1.09) 0.002 1.07 (1.03-1.12) 0.002 1.06 (1.02-1.10) 0.003 1.09 (1.02-1.17) 0.009 
Ca19.9‡ baseline, IU/mL 1.03 (1.01-1.05) 0.03 0.97 (0.93-1.02) 0.18 1.04 (1.01-1.07) 0.02 1.06 (0.98-1.14) 0.16 
Ca125 baseline, IU/mL 1.001 (0.99-1.01) 0.15 - - 1.001 (0.99-1.01) 0.17 - - 
* The test of proportional-hazards assumptions was tested in both multivariable analyses and showed that proportionality assumption in the cox 
regression was held (p-value for iCCA model 0.6544; p-value for iCCA with liver-only disease model was 0.9550). HR: Hazard Ratio; CI: 
confidence interval; iCCA: intrahepatic cholangiocarcinoma; n: number of patients; Dif: differentiation; Ref: group of reference; ECOG: Eastern 
Cooperative Oncology Group; nr: not reached; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CEA: carcinoembryonic 
antigen; Ca 19.9: Serum carbohydrate antigen; Ca125: cancer antigen 125; nc: not calculated (due to collinearity); n/a: not applicable. 
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† Cox Regression was employed for this analysis; P values are two-sided. 
‡ For the purpose of survival analyses, CEA and Ca19.9 variables were modified in order to obtain a clinically meaningful HR; CEA is 
presented as CEA/10 and Ca19.9 as CA19.9/10.000. Therefore, HR represents increase risk of death by every increase of 10 units and 10,000 
units of CEA and Ca19.9, respectively.  
$  
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Table 4: Reported studies of radioembolisation in intrahepatic cholangiocarcinoma 
Reference Study design  
No. of 
patients 
Patient outcomes Level of evidence* 
Al-Adra et al 23014 
(40) Systematic review 298 
Median OS: 15.5 months. 
Radiological response: partial response in 28% and stable disease in 
54% of patients at three months. 
Level C 
Mouli et al 2014 (55) 
Prospective single 
centre  
46 
Radiological response: partial response (n=11; 25%), stable disease 
(n = 33; 73%), and progressive disease (n=1; 2%).One patient did 
not have information regarding response to treatment. 
Level C 
Edeline et al 2017 (45) 
Prospective phase II 
study 
45 
Cisplatin/gemcitabine day 1 and 8 of a 21-days cycles; 
radioembolisation delivered during cycle 1 (unilobar disease), or 
cycles 1 and 3 (bilobar disease). 
Radiological response: partial response (39%, 90% CI = 26-53); 
disease control rate 98% (all 40 evaluable patients had disease 
control). Median PFS and OS from time of starting chemotherapy 
were Median PFS was 13 months (95%CI = 7-nr) and 21 months 
(95%CI = 14-nr), respectively. 
Level C 
Hoffmann et al 2012 
(56) 
Prospective single 
centre 
33 
Radiological responses: 12 patients had a partial response, 17 had 
stable disease, and 5 had progressive disease after 3 months. 
Median OS from the time of diagnosis and first radioembolisation 
procedure was 43.7 months and 22 months, respectively. Median 
TTP was 9.8 months. 
Level C 
Saxena et al  2009(57) Prospective study 25 
The median OS (following radioembolisation): 9.3 months. 
Radiological response: partial response to treatment was observed in 
6 patients (24%), stable disease in 11 patients (48%), and 
progressive disease in 5 patients (20%). 
Level C 
Rafi et al 2013 (58) 
Prospective single 
centre 
19† 
Median OS from the time of diagnosis and first radioembolisation 
procedure was 24.7 months (752 days, 95%CI = 374-1130) and 11.3 
months (345 days; 95%CI = 95-595), respectively. 
Level C 
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Hyder et al 2013 (38)  
Retrospective 
multicentre review 
198‡ Median OS: 11.3 months. Level C 
Gangi et al 2018 (59) 
Retrospective single 
centre 
85§ 
Median OS from diagnosis and from radioembolisation was 21.4 
(95%CI = 16.6-28.4) and 12.0 months (95%CI = 8.0-15.2), 
respectively. 
At 3 months, 6.2% of patients had partial response,  
Level C 
Edeline et al 2015 (60) 
Retrospective single 
centre 
24 
Sequencing of chemotherapy and radioembolisation: concomitant 
chemotherapy in 10 patients (42%), chemotherapy as induction 
before RE in 13 (54%) or after RE in 1 (4%). 
From the start of any treatment, the median PFS was 16.0 months. 
Median OS: not reached. 
Level C 
Ibrahim et al 2008 (42) 
Open-label cohort 
study 
24 
Radiological response: 22 patients evaluable: 6 (27%) achieved a 
partial response, 15 (68%) stable disease and 1 patient (5%) 
progressive disease. 
The median OS was 14.9 months. 
Level C 
*The following definitions of level of evidence were used (52): Level A: there exists a meta-analysis of high standard or several randomised 
trials with consistent results; Level B: if randomised studies (level B1), therapeutic trials, quasi-experimental trials, or comparisons of 
populations (level B2) provide consistent results when considered together; Level C: there exist studies, therapeutic trials, quasi-experimental 
trials, or comparisons of populations, of which the results are not consistent when considered together; Level D: if either scientific data does not 
exist or there is only a series of cases; expert agreement: data does not exist but the experts are unanimous in their judgment. TTP: time-to-
progression; PFS: progression-free survival; OS: overall survival; nr: not reached; CI: confidence interval. 
† All patients were refractory to standard chemotherapy 
‡ Patients in total (23.2%; 45 patients were intrahepatic cholangiocarcinoma) 
§ Consecutive patients
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Figure titles and legends 
 
Figure 1: Prognosis of cisplatin/gemcitabine-treated patients.  
Median overall survival estimated by Kaplan-Meier for each subgroup is shown. Patients for 
whom survival data was not available are excluded from this graph. Therefore, number of 
patients at risk [BTC (309 patients), BTC (non-iCCA) (245 patients), iCCA (64 patients); 
iCCA (liver-only) (32 patients) and iCCA (non-liver-only) (32 patients)] may not match with 
the total number of patients included in each group [BTC (328 patients), BTC (non-iCCA) 
(262 patients), iCCA (66 patients); iCCA (liver-only) (34 patients) and iCCA (non-liver-only) 
(32 patients)]. Univariate and multivariable Cox Regression results (as per Supplementary 
Table 3; if applicable) are provided: Figure 1.A shows OS for all BTC patients. Figure 1.B 
shows comparison between other BTC (non-iCCA) (Reference group) and iCCA. Figure 1.C 
shows comparison between other BTC (non-iCCA) (Reference group) and iCCA (liver-only). 
Figure 1.D shows comparison between iCCA (liver-only) and iCCA (non-liver-only) 
(Reference group). All statistical tests were two-sided.  
uHR: Univariate hazard ratio; aHR: adjusted multivariable hazard ratio; 95%CI: 95% 
confidence interval; BTC: biliary tract cancer (includes gallbladder, ampulla and 
cholangiocarcinoma); iCCA: intrahepatic cholangiocarcinoma; m: months.  
 
Figure 2: Potential trial designs for incorporating liver-directed therapy (LDT) to the 
management pathway of patients with iCCA. Figure includes details regarding percentage 
of patients potentially eligible for LDT (defined as liver-only disease; calculated using the 
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whole iCCA population as reference) and expected outcomes with cisplatin/gemcitabine for 
each potential scenario. 
R: randomisation; iCCA: intrahepatic cholangiocarcinoma; LDT: liver-directed therapy; PFS: 
progression-free survival; OS: overall survival; 95%CI: 95% confidence interval; % 
percentage.  
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Figure 1 blackandwhite
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Figure 2 blackandwhite
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